Table 1 Baseline characteristics of study participants according to ALP tertiles.
ALP tertiles | ||||||||
|---|---|---|---|---|---|---|---|---|
1st tertile (ALP < 196 U/L) | 2nd tertile (196 U/L < = ALP < 274 U/L) | 3rd tertile (274 U/L < = ALP) | ||||||
Missing (%) | Overall | Control Group | Oral Alfacalcidol Group | Control Group | Oral Alfacalcidol Group | Control Group | Oral Alfacalcidol Group | |
N | 964 | 155 | 165 | 158 | 161 | 160 | 160 | |
Age (median [IQR]), y | 0.0 | 65 [58, 71] | 63 [55, 69] | 62 [54, 67] | 65 [59, 71] | 66 [60, 70] | 66 [60, 73] | 68 [60, 72] |
Sex, Female % (freq) | 0.0 | 40.0 (386) | 32.3 (50) | 38.2 (63) | 45.6 (72) | 32.3 (52) | 46.9 (75) | 44.4 (71) |
Dialysis duration (median [IQR]), y | 0.0 | 5 [2, 11] | 4 [2, 9] | 5 [2, 10] | 5 [2, 11] | 5 [2, 10] | 7 [3, 15] | 6 [3, 12] |
CV comorbidities, % (freq) | 0.0 | 25.3 (244) | 20.0 (31) | 24.8 (41) | 24.1 (38) | 28.0 (45) | 29.4 (47) | 25.0 (40) |
sBP (median [IQR]), mmHg | 0.0 | 146 [133, 160] | 147 [134, 160] | 148 [133, 162] | 149 [136, 162] | 143 [130, 161] | 148 [134, 160] | 145 [129, 156] |
DM % (freq) | 0.0 | 46.0 (443) | 47.7 (74) | 37.6 (62) | 48.7 (77) | 50.9 (82) | 46.2 (74) | 45.6 (73) |
BMI (median [IQR]) | 2.0 | 21.1 [19.1, 23.3] | 21.6 [19.6, 23.4] | 21.5 [19.5, 23.4] | 21.0 [18.9, 23.2] | 20.8 [19.1, 23.2] | 20.7 [18.7, 23.1] | 20.7 [18.9, 23.3] |
CRP (median [IQR]), mg/dL | 12.8 | 0.10 [0.05, 0.29] | 0.09 [0.05, 0.26] | 0.08 [0.05, 0.19] | 0.10 [0.05, 0.23] | 0.10 [0.06, 0.30] | 0.11 [0.06, 0.32] | 0.12 [0.06, 0.39] |
ALP (median [IQR]), U/L | 0.5 | 234 [183, 296] | 164 [141, 183] | 166 [146, 183] | 234 [217, 255] | 234 [218, 251] | 328 [298, 386] | 333 [295, 382] |
Alb (median [IQR]), g/dL | 0.1 | 3.8 [3.5, 4.0] | 3.8 [3.6, 4.0] | 3.8 [3.6, 4.0] | 3.7 [3.6, 3.9] | 3.8 [3.6, 4.0] | 3.7 [3.5, 3.9] | 3.7 [3.5, 3.9] |
P (median [IQR]), mg/dL | 0.0 | 4.7 [3.9, 5.3] | 5.0 [4.2, 5.5] | 4.7 [4.0, 5.4] | 4.7 [3.9, 5.3] | 4.5 [3.8, 5.1] | 4.5 [3.8, 5.3] | 4.6 [3.9, 5.1] |
Corrected Ca (median [IQR]), mg/dL | 0.0 | 9.1 [8.8, 9.5] | 9.2 [8.9, 9.6] | 9.2 [8.9, 9.6] | 9.1 [8.7, 9.5] | 9.1 [8.6, 9.4] | 9.0 [8.7, 9.4] | 9.1 [8.8, 9.4] |
iPTH (median [IQR]), pg/mL | 0.0 | 85 [46, 129] | 78 [45, 112] | 83 [46, 125] | 91 [45, 128] | 82 [38, 130] | 97 [57, 145] | 101 [51, 132] |
Hb (median [IQR]), g/dL | 0.0 | 10.6 [10.1, 11.3] | 10.6 [10.0, 11.3] | 10.7 [10.1, 11.3] | 10.8 [10.1, 11.4] | 10.6 [10.1, 11.1] | 10.7 [10.1, 11.4] | 10.7 [10.0, 11.5] |
HDLC (median [IQR]), mg/dL | 8.6 | 46 [37, 56] | 46 [36, 55] | 46 [38, 58] | 47 [37, 55] | 46 [37, 56] | 47 [39, 56] | 45 [38, 54] |
ESA use, % (freq) | 0.0 | 34.5 (333) | 31.0 (48) | 34.5 (57) | 32.3 (51) | 31.7 (51) | 38.1 (61) | 38.1 (61) |
